UPDATE: Citi Lowers Price Target On Human Genome Sciences To $15
According to Citi, Human Genome Sciences (NASDAQ: HGSI) price target is lowered to $15.
Citi said that it is lowering its Benlysta ests due to a slower U.S. launch and more modest peak sales potential, it is lowering its TP to $15 (-$11) based on DCF. “This is based on our IMS sales tracker and doc checks that show more lukewarm reception to Benlysta than we originally expected.”
Human Genome Sciences closed yesterday at $13.41.
(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
We're Loving
